Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

NCT05576181 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

Interventions

DRUG: ThisCART19A
DRUG: Fludarabine Oral Tablet
DRUG: Cyclophosphamide
DRUG: VP-16
PROCEDURE: HSCT

Sponsor

Fundamenta Therapeutics, Ltd.

Collaborators

[object Object]